APOTHECA SYSTEMS REVEALS THE FIRST AI BASED PERSONALIZED THERAPY FRAMEWORK AND DISCOVERY PLATFORM TO REVOLUTIONIZE CANNABIS AND PSYCHEDELIC ASSISTED PSYCHOTHERAPY
September 8th, 2020
Psychedelics, Top News
VANCOUVER, British Columbia, September 8th, 2020 – Apotheca Systems Inc. (“Apotheca” or “the Company”), an applied AI for evidence based natural medicines company with an emphasis on AI assistance for cannabis and psychedelic based therapy, is pleased to announce the next development phase of its patent pending AI Assisted Personalized Therapy Framework Platform, Apotheca.ai.
With the promise of psychedelic medicine moving into the mainstream, Apotheca is strategically positioned to help enhance the lives of those seeking effective mental health treatment through cannabis, psychedelics and psychedelic-enhanced psychotherapy.
Mental disorders increasingly contribute to the global burden of disease, with huge socio-economic costs. Globally, more than 264 million people of all ages suffer from depression. Women are twice as likely as men to develop PTSD during their lifetime, and three times as likely to develop the disorder annually. These numbers are forecasted to increase significantly during the global pandemic.
Apotheca’s new platform is dedicated to the alleviation of this global crisis by leveraging data and machine learning to help therapists, health professionals and their clients cost effectively embrace and engage new personalized therapies and evidence based natural medicines in mental health treatment. “In the last few years, we have seen incredible new research results and advances in our understanding of how these compounds work in the brain. This evidence is changing how we look at mental health treatment.” stated Chris Boothroyd, Apotheca Systems CEO. He continued “We believe it is time to begin applying the concepts of personalized precision medicine, AI and cross disciplinary research to better understand and predict how individual genetics, biological phenotypes and mental states align with responses to these new interventions. This will enable us to offer a better decision support system for therapists and
their clients, to deliver the best set of statistically derived therapy framework options for mental health treatment.”
Apotheca began by adopting the principles of the new medical movement towards personalized and precision health. At the core of this movement is a holistic approach to medicine, looking at the individual as a tightly bound biological interplay of genetics, the body and the mind, how these three things work together to make us who we are and the acceptance that every individual’s therapy is unique.
Using this approach, the Apotheca.ai platform leverages permissioned and anonymized cannabis and psychedelic clinical trial and therapy data to drive its machine learning process. This is used to help create a unique biomarker profile of each individual across genetics, phenotypes and cognitive states, and predict which therapy framework configurations will be most effective. This includes client intake, harm reduction, set and setting, therapy, post-therapy integration and longitudinal follow-up.
“Our platform is the first to tackle the need for AI assisted therapy personalization head on. We have found a way to harness everyone’s uniqueness, to better predict and identify highly effective therapy frameworks for individuals.” stated Kirsten Tomilson, Apotheca Chief Research Officer. ”Apotheca has found a way to statistically predict the effectiveness of many different possible therapy framework configurations and step away from a monolithic drug centric approach. One size does not fit all”
The Apotheca.ai platform offers a secure collaborative environment and toolset for the therapist to work with the client for biomarker collection and the personalization of their therapy framework. The platform will be free to use for therapists, health professionals and clients, with subscription options available to further customize therapy framework planning, sessions and follow-up.
“We were inspired by the early research we started in 2017 in the cannabis space and decided to quickly build the Apotheca team, file the first applied AI patent and figure out how to scale the personalization and optimization of outcomes across many different conditions.” said Boothroyd. “Apotheca is proud to say that we are now at the stage where we are expanding the early platform development to include more cannabis and psychedelic ecosystem partners who share this vision. It’s time to bring the power of AI to therapists and reinforce the importance of their critical role in the maintenance of good health.”
Apotheca is looking for other like-minded ecosystem partners to join the platform and help build an important step in the use of AI and personalized precision medicine for the treatment of mental health. Interested parties should contact [email protected] for partner program details and further information.
Apotheca.ai is pioneering in the new field of Applied AI for Evidence Based Natural Medicines by harnessing the power of personalized precision medicine, health informatics and artificial intelligence.
Apotheca’s AI Assisted Therapy & Discovery Framework platform is being built to provide a fully collaborative suite of therapy framework personalization tools, giving therapists and their clients the best possible recommendations for a complete longitudinal therapy configuration. Permissioned and anonymized data is collected to drive the machine learning process, to provide high efficacy therapy framework recommendations and predict new areas of biological systems research and new intervention candidates. Learn more at: www.apotheca.ai
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.